After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor

blonca9
2 days ago
1 min read

Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to lower LDL by over 50% in patients with a genetic form of hypercholesterolemia.

Recent Posts

See All

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target

After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight